Related Experiment Videos
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Brain cannabinoid systems as targets for the therapy of neurological disorders.
Neurobiology of disease·1999
AM630 is an inverse agonist at the human cannabinoid CB1 receptor.
Life sciences·1998
Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain.
European journal of pharmacology·1998
SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.
European journal of pharmacology·1997
delta 9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain.
European journal of pharmacology·1997
AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain.
European journal of pharmacology·1997
A Rare Case of Storage Mite Anaphylaxis in Infancy.
The Medical journal of Australia·2026
The Impact of Heat and Bushfire Smoke on Health System Utilisation in Australia.
The Medical journal of Australia·2026
Unshrouding Social Determinants: A Case for Standardised Data in Australia's Health Information Ecosystem.
The Medical journal of Australia·2026
Getting on the Same Page: Why Australia Needs a National Maternity Early Warning System (MEWS) Chart.
The Medical journal of Australia·2026
Roadmap to Support International Medical Graduates for Satisfying Rural General Practice Careers: A Realist Evaluation Approach.
The Medical journal of Australia·2026
Research Priority Setting Is Not Research: A Call for Ethical Clarity in Australia.
The Medical journal of Australia·2026
Natural Product Echinocandin Derivative S4286 Induces Mitochondrial Dysfunction to Combat Sclerotinia sclerotiorum.
Journal of agricultural and food chemistry·2026
From SHP2 to DDR1-ERK: A critical signaling axis controlling microglial activation and neuropathic pain after spinal cord injury.
General physiology and biophysics·2026
Association of Cannabis Use With Risk of Subsequent Falls Among Adults Aging With HIV.
Open forum infectious diseases·2026
Bestatin inhibits the development of cutaneous melanoma by inhibiting the expression of LTA4H.
Frontiers in immunology·2026